TraceLink customers receive EMVO approval for data submission to EU Hub

6 Jun 2018

Company has developed a standard feature for its customers to execute the EMVO conformance testing successfully.

TraceLink has developed a streamlined program for its 190+ customers to rapidly complete conformance testing and successfully receive European Medicines Verification Organization (EMVO) approval to submit data to the EU Hub - a complex and lengthy process that requires each company to complete EMVO registration and provide a full set of test cases to be executed for conformance with the EU Hub.

TraceLink customers receive EMVO approval for data submission to EU Hub

In just one month, 34 companies have completed their conformance testing with TraceLink’s conformance test kit. Of these, 11 companies have received EMVO approval to submit data to the EU Hub and 14 companies are awaiting review from the EMVO. To achieve final approval, all pharmaceutical companies must now submit a series of transactions to be reviewed by the EMVO, a process that can now take several weeks due to the surge of companies seeking to connect to the EU Hub before the EU Falsified Medicines Directive (FMD) deadline in February 2019. Once the transactions are approved by the EMVO, a pharmaceutical company will receive access to the certificates required for production and data submission to the EU Hub.

To accommodate the more than 190 customers that have selected TraceLink to help meet their EU Falsified Medicines Directive (FMD) requirements, TraceLink has developed a standard feature for its customers to execute the EMVO conformance testing successfully, including specific product functionality and services optimized to help guide customers through the EMVO approval process for connection to the EU Hub. After executing a conformance test, any TraceLink customer using the EU compliance module will receive automatically generated files that are ready to be submitted to the EU Hub for approval.

“The EMVO has stated that there is no longer a formal certification for pharmaceutical companies or solution providers to gain access to the EU Hub, so pharmaceutical companies that are still evaluating solutions should be skeptical of any vendor statements claiming they are ‘EMVO certified.’ The true test is demonstrating how many pharmaceutical companies have actually achieved EMVO approval using a particular solution provider, as this validates correct use of the EU Hub integration APIs,” said Shabbir Dahod, president and CEO of TraceLink. “TraceLink’s history integrating with the EU Hub dates back 2 years, with nearly 650,000 serial numbers submitted to the EU Hub by our customers since 2016. Today, while other solution providers are in the midst of conducting pilot tests and resorting to promotional discount strategies in an attempt to acquire new customers, TraceLink customers are out front, already live in production with serialization and officially approved to submit data to the EU Hub.”

“After working with TraceLink to successfully complete our conformance testing, we have received EMVO approval to begin submitting data to the EU Hub, nearly 10 months ahead of the EU FMD deadline,” said Ortwin Kottwitz, CEO of biosyn. “Gaining EMVO certification with the TraceLink conformance test kit was simple and straightforward, and with TraceLink’s multi-tenant approach, we are well-positioned for continued certification despite any unforeseen changes to our systems in the future.”

Read More

Related news

New portable and ready-to-use upper respiratory drug delivery solution

New portable and ready-to-use upper respiratory drug delivery solution

11 Oct 2018

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

Read more 
CPhI Worldwide announces the winners  of the 15th Pharma Awards

CPhI Worldwide announces the winners of the 15th Pharma Awards

10 Oct 2018

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

Read more 
CMOs to benefit from double digit approvals for ADCs in the next 3 years

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Read more 
Micro-Sphere increases capsule filling capacity

Micro-Sphere increases capsule filling capacity

8 Oct 2018

The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

Read more 
Symbiosis secures FDA viral vector process approval

Symbiosis secures FDA viral vector process approval

5 Oct 2018

Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.

Read more 
Three-way collaboration to advance gene therapy

Three-way collaboration to advance gene therapy

4 Oct 2018

Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

Read more 
New horizontal flow wrapping machine for hermetic packages

New horizontal flow wrapping machine for hermetic packages

3 Oct 2018

Greater product protection thanks to reliable sealing technologies.

Read more 
Movement on the market reflected at CPhI Worldwide 2018

Movement on the market reflected at CPhI Worldwide 2018

3 Oct 2018

Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

Read more 
Niche CDMO confirms spray drying for highly potent drugs

Niche CDMO confirms spray drying for highly potent drugs

1 Oct 2018

Idifarma's GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.

Read more 
Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions

Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions

1 Oct 2018

The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.

Read more